The short answer
A published safety literature exists. Reid and colleagues reported atypical melanocytic naevi following melanotan injection in the Irish Medical Journal in 2013, and Eijmael and colleagues reviewed the risks in the Nederlands Tijdschrift voor Geneeskunde in 2022. This is documented clinical concern rather than speculation.
Key facts
- Reid 2013
- Ir Med J: atypical melanocytic naevi
- Eijmael 2022
- Ned Tijdschr Geneeskd: risk review
- Literature type
- Case reports and clinical reviews
- Setting
- Dermatology
- Product type
- Unlicensed injectable
- Regulatory assessment
- None conducted
Why this is stated rather than omitted
An unlicensed injectable compound with published dermatological case reports is a situation where withholding the literature would be the wrong editorial choice. The reports exist in indexed medical journals and are straightforwardly findable. Presenting the compound without them would give an incomplete picture of what is known.
What the case reports describe
Reid and colleagues documented atypical melanocytic naevi appearing following melanotan injection, published in the Irish Medical Journal in 2013. Melanocytic naevi are pigmented lesions, and changes in them are exactly what dermatological surveillance exists to detect. Case reports establish that something was observed and documented in identified patients.
Research material referenced
MT-2 10mg, third-party HPLC tested
What a case report can and cannot establish
It establishes an observation. It does not establish causation, incidence or risk, because there is no denominator (no count of how many people used the compound without the outcome). This is the same limitation that applies to pharmacovigilance disproportionality signals, and it cuts both ways: a case report is not proof of harm, and it is not dismissible either.
The 2022 review
Eijmael and colleagues published on the risks of tanning with this compound class in the Nederlands Tijdschrift voor Geneeskunde in 2022. A national medical journal publishing a risk review indicates the clinical community considered the topic worth addressing directly.
Why an unlicensed injectable is a distinct category of concern
No regulator has assessed this compound's safety, so there is no label, no contraindications, no adverse event reporting requirement and no monitoring framework. The information that would normally exist simply does not. What is available instead is what individual clinicians have chosen to publish after seeing something.
What is claimed here
Nothing about what this compound does or does not do in any person. This article reports that a published safety literature exists and what it contains. Material supplied here is for laboratory research only.
Frequently asked questions
What are the side effects of Melanotan 2?
The literature reports nausea, facial flushing, spontaneous erections and, most significantly, changes to existing naevi (moles darkening, enlarging or becoming atypical), with case reports linking melanotan use to melanoma. These come from case reports and small series, not controlled trials.
Does Melanotan 2 change eye colour?
Iris darkening is reported anecdotally and is biologically plausible, since the iris contains melanocytes expressing melanocortin receptors. It is not documented in controlled studies, and any such change would not be expected to reverse.
Is Melanotan 2 permanent?
Pigmentation is not permanent. Melanin is lost as skin cells turn over, so it fades over weeks once the stimulus stops. Changes to moles are a different matter and are not assumed to reverse.
Is there published safety literature on MT-2?
Yes: case reports of atypical melanocytic naevi following injection in the Irish Medical Journal in 2013, and a 2022 risk review in a Dutch medical journal.
Do case reports prove harm?
No. They establish an observation without a denominator, so they cannot establish causation or incidence. They are also not dismissible.
Why does unlicensed status matter for safety?
There is no label, no contraindications, no adverse event reporting requirement and no monitoring framework. The information that would normally exist does not.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedReid C et al., Atypical melanocytic naevi following melanotan injection. Ir Med J 2013 (PMID 23914578)pubmed.ncbi.nlm.nih.gov
- PubMedEijmael MJPM et al., The risks of tanning with the Barbie drug. Ned Tijdschr Geneeskd 2022 (PMID 35736369)pubmed.ncbi.nlm.nih.gov
- RefMHRA: Medicines and Healthcare products Regulatory Agencygov.uk
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More MT-2 (Melanotan II) articles
- Melanotan 2 Storage, Mixing and StabilityCyclisation, a D-amino acid and two capped termini make this among the most chemically stable peptides in the catalogue.
- Does Melanotan 2 Work Without UV?The receptor mechanism does not require UV, and the approved analogue proves pigmentation can rise without it. What that does and does not establish for MT-2.
- Melanotan 2 Onset: What Can and Cannot Be SaidNo controlled trial has measured a time course for MT-2. What melanin biology sets as a floor, and what the licensed analogue's data actually shows.
- Why This Site Publishes No Melanotan 2 DoseNot evasion - there is no established human dose to publish. The compound is unauthorised, the MHRA has warned about it, and the reported harms are specific.
- What Before-and-After Photographs Can and Cannot ShowLighting, camera and sun exposure vary more between photographs than skin does. What would count as evidence, and what the licensed analogue measured.